Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Clinical trial NCT05216263 · COMPLETED
Trial details
- NCT number
- NCT05216263
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2025-05-02
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.